PHARNEXT
Regulatory News:
Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced that Rodolphe Hajj, Ph.D., the Company’s Chief Pharmacology Officer, will present at the 8th Annual Global Orphan Drug Conference.
The presentation will take place as follows:
- Date & Time: Wednesday April 25th at 4:40 pm EST
- Title: “Next generation drug repurposing using network pharmacology to develop new therapeutic entities for rare diseases”
- Venue: Gaylord National Harbor Hotel, Oxon Hill, MD, U.S.
Pharnext’s team will also attend the 2018 American Academy of Neurology Annual Meeting as a first-time exhibitor (booth 908). The meeting will take place on April 21-27, 2018 in Los Angeles, CA, U.S.
If you are interested in meeting the Pharnext management team during these events, please send an email to contact@pharnext.com .
About Pharnext
Pharnext is an advanced clinical-stage
biopharmaceutical company developing novel therapeutics for orphan and
common neurodegenerative diseases that currently lack curative and/or
disease-modifying treatments. Pharnext has two lead products in clinical
development. PXT3003 is currently in an international Phase 3 trial for
the treatment of Charcot-Marie-Tooth disease 1A type and benefits from
orphan drug status in Europe and the United States. The results of this
trial are expected in the second half of 2018. PXT864 has generated
positive Phase 2 results in Alzheimer’s disease. Pharnext has developed
a new drug discovery paradigm based on big data genomics and artificial
intelligence: PLEOTHERAPY™. The Company identifies and develops synergic
combinations of drugs called PLEODRUG™ offering several key advantages:
efficacy, safety and robust intellectual property. The Company was
founded by renowned scientists and entrepreneurs including Professor
Daniel Cohen, a pioneer in modern genomics, and is supported by a
world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN
code: FR0011191287).
For more information, visit www.pharnext.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180419005935/en/
Contact:
Pharnext
Xavier Paoli
Chief Commercial Officer
+33
(0)1 41 09 22 3030
contact@pharnext.com
or
Investor
Relations (Europe)
MC Services AG
Anne Hennecke
+49
211 529252 22
anne.hennecke@mc-services.eu
or
Investor
Relations (U.S.)
Stern Investor Relations, Inc.
Matthew
Shinseki
+1 212 362 1200
matthew@sternir.com
or
Financial
Communication (France)
Actifin
Stéphane Ruiz
+33 (0)1
56 88 11 15
sruiz@actifin.fr
or
Media
Relations (Europe)
ALIZE RP
Aurore Gangloff
Caroline
Carmagnol
+33 (0)1 44 54 36 66
pharnext@alizerp.com
or
Media
Relations (U.S.)
RooneyPartners
Kate Barrette
+1 212
223 0561
kbarrette@rooneyco.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MOOVE19.3.2024 09:02:26 CET | Press release
Moove secures USD $100 million Series B round
WI-CIELO19.3.2024 08:12:25 CET | Press release
Cielo Debuts First Generative AI for Talent Acquisition: CLO.ai
GALDERMA19.3.2024 07:01:34 CET | Press release
AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio
CA-NETAPP18.3.2024 23:01:28 CET | Press release
NetApp Empowers Customers to Securely “Talk to Their Data” in Collaboration with NVIDIA
KPMG18.3.2024 18:39:35 CET | Press release
KPMG’s "Digital Gateway for Tax" Platform Raises Global Standards in Tax Functionality with Generative AI
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom